… transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced … 30 days following the presentation date. About Axiomer ® ProQR is pioneering a next-generation RNA base …
… N.V. entered into a research collaboration to apply the Axiomer ® RNA editing technology to fibrosis targets selected … research collaboration with Galapagos, where the company’s Axiomer ® technology will be applied to certain fibrosis … partnering and other strategic relationships for the Axiomer ® platform in select therapeutic areas Entered into a …
… Scientific Officer role, with leadership oversight of Axiomer ® RNA-editing platform technology John Maraganore, … to provide strategic oversight of ProQR’s proprietary Axiomer RNA-editing platform technology. He is the scientific … new strategy, including further building out the Company’s Axiomer RNA-editing technology as a value-generating …
… X: Late-breaking clinical studies Poster presentation on Axiomer ® RNA editing technology A presentation will be … PhD, Sr. scientist computational analytics of ProQR on the Axiomer ® RNA editing technology. Poster title: … Western world have LCA10 because of this mutation. About Axiomer ® Technology Platform ProQR is pioneering a …
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022
Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retini
… based on novel RNA editing technologies including our Axiomer ® technology." Dr. Yu is a professor of biochemistry … that do not currently have treatment options." About Axiomer ® Technology Platform ProQR is pioneering a next-generation RNA technology called Axiomer ® , which could potentially yield a new class of …
… in patients with LCA10 and preclinical data for ProQR’s Axiomer ® RNA-editing technology. Abstract titles: ○ … through intravitreal injections in the eye. About Axiomer ® Technology Platform ProQR is pioneering a next-generation RNA technology called Axiomer ® , which could potentially yield a new class of …